Hong Kong-based biotech InSilico Medicine has used artificial intelligence (AI) to create the drug INS018-055 to help treat idiopathic pulmonary fibrosis (IPF).
IPF is a disease whereby the tissue surrounding the alveoli in the lungs becomes inflamed and thick, causing scarring within the lungs. This causes the lungs to become increasingly stiff, making it difficult for respiration. Pirfenidone and nintedanib are the two main medications used to help delay the progression of IPF.
Pirfenidone works by suppressing the activity of the immune system, whereas nintedanib works by helping slow down the progression of scarring within the lungs. InSilico’s INS-08055 acts by targeting discoidin domain receptor 1 (DDR1). INS-08055 acts by inhibiting DDR1, a collagen-activated pro-inflammatory receptor tyrosine kinase, expressed in epithelial cells and involved in fibrosis. The drug candidate, by inhibiting DDR1, alleviates the disease condition and is administered through intravenous and oral routes. Unlike other AI-produced drugs in trials, INS018_055 is the first drug with both a novel AI-discovered target and a novel AI-generated design.
According to GlobalData’s Clinical Trials Database, the Phase II trial is currently ongoing and recruiting and is a double-blind, randomised trial investigating the safety, tolerability, pharmacokinetics, and efficacy of INS018_055 administered orally in subjects with idiopathic pulmonary fibrosis. The study includes subjects with IPF divided into four parallel cohorts. To evaluate the drug in wider populations, there are study plans to enrol 60 subjects with IPF at about 40 sites in both the US and China.
Currently, InSilico Medicine has six trials listed on GlobalData’s Clinical Trials Database, two being completed, two ongoing and recruiting, one planned, and one that was terminated.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData